Edwards Lifesciences Reports Q1 2024 Financial Results and Raises Guidance

Details

The company reported Q1 EPS of $0.58 and adjusted EPS of $0.66. Edwards Lifesciences raised its 2024 sales guidance to the high end of the previous 8 to 10% range, now expecting full-year sales growth to be at the high end of the prior guidance of 8 to 10% and $6.3 to $6.6 billion. The company also raised full-year 2024 sales guidance for Transcatheter Mitral and Tricuspid Therapies (TMTT) and Surgical Structural Heart, and is confident in TAVR guidance. The company is on track for the spin-off of its Critical Care business by year-end.

Items reported

Exhibits (1)

About Edwards Lifesciences Corporation

Edwards Lifesciences Corporation is a leading healthcare company primarily known for its innovative medical devices focused on cardiovascular conditions. The firm's primary function revolves around the development and commercialization of heart valve products and hemodynamic monitoring systems, aimed at enhancing the life quality of patients suffering from cardiovascular diseases. Edwards Lifesciences plays a crucial role in the healthcare sector, particularly impacting the cardiology and surgical fields. Notable for its pioneering work in heart valve therapies, the corporation is at the forefront of transcatheter aortic valve replacement (TAVR) technology, a minimally invasive procedure that offers a significant alternative to traditional open-heart surgeries. Edwards Lifesciences collaborates closely with healthcare professionals to ensure its products address critical medical needs globally. Headquartered in Irvine, California, Edwards Lifesciences operates in a highly competitive and rapidly advancing market, where technological innovation and patient outcomes are pivotal. Its contributions continue to set standards within the medical device industry, reinforcing its market significance by addressing demands for effective cardiovascular care solutions worldwide.